Tempest Therapeutics Activates $50M Lincoln Park Equity Line — 8.9M Shares Registered for Resale
TPST sits 25% above its 52-week low of $0.84.
Summary
Tempest Therapeutics' $50 million Lincoln Park equity line is now effective, with 8.9 million shares registered for resale. The facility provides critical liquidity for the cash-strapped biotech but carries deep-discount pricing that will likely pressure the stock.
Key Events · Financing and Capital Events · TPST
-
Equity Line Activated
The $50 million Lincoln Park equity line is now effective, with 8,910,579 shares registered for resale — 560,356 Initial Commitment Shares already issued, 350,223 Additional Commitment Shares pending, and 8,000,000 shares available for future sales.
-
Deep-Discount Pricing Terms
Regular Purchases are priced at 97% of the lower of the purchase-date low or the 10-day average of the three lowest closes; Accelerated Purchases at 96% of the lower of VWAP or closing price — enabling Lincoln Park to resell immediately at a profit.
-
Dilution Impact
If all 8,000,000 shares are issued, outstanding shares would rise from 16,539,767 to 24,889,990 — approximately 33% dilution to existing holders, with the new shares representing about 50% of the non-affiliate float.
-
Proceeds Reality Check
At the illustrative $1.02 purchase price (August 20, 2026 close), selling all 8,000,000 shares would raise only $8.16 million gross — far below the $50 million headline commitment.
Analysis · TPST · Life Sciences
This prospectus makes effective the $50 million equity line with Lincoln Park Capital Fund, first registered on August 21, 2026. The filing adds critical pricing mechanics: Regular Purchases are priced at 97% of the lower of the purchase-date low or the 10-day average of the three lowest closes, while Accelerated Purchases carry a 96% discount. With only $0.8 million in cash reported in Q2 2026 and a going-concern warning outstanding, this facility is the company's primary liquidity lifeline. However, the deep discount structure means Lincoln Park can resell shares immediately at a profit, creating persistent selling pressure. At the illustrative $1.02 price, the full 8 million shares would raise only $8.16 million — far below the $50 million headline — and dilute existing holders by roughly 33%.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 40% of the 987 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TPST was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.8M. The 52-week trading range was $0.84 to $12.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.